Paraprotein-related kidney disease: Glomerular diseases associated with paraproteinemias

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 12, 2016, Pages 2260-2272

  Motwani, Shveta S ^a,b   Herlitz, Leal ^c   Monga, Divya ^d   Jhaveri, Kenar D ^e   Lam, Albert Q ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^e Northwell Health   (United States)

Author keywords

Amyloidosis; Cast nephropathy; Kidney; Kidney Diseases; Light chains; Monoclonal paraprotein; Multiple myeloma M proteins; Myeloma Proteins; Paraproteins; Social Behavior

Indexed keywords

AZATHIOPRINE; BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; MYCOPHENOLATE MOFETIL; PARAPROTEIN; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; RAPAMYCIN; RITUXIMAB; STEROID; THALIDOMIDE; VINCRISTINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

AL AMYLOIDOSIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW BIOPSY; CHRONIC LYMPHATIC LEUKEMIA; CRYOGLOBULINEMIA; ELECTRON MICROSCOPY; END STAGE RENAL DISEASE; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN DEPOSITION; KIDNEY BIOPSY; MULTIPLE MYELOMA; PARAPROTEINEMIA; PLASMAPHERESIS; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; AMYLOIDOSIS; COMPLICATION; GLOMERULONEPHRITIS; GLOMERULUS; IMMUNOLOGY; KIDNEY DISEASE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; METABOLISM; PATHOLOGY;

AMYLOIDOSIS; CRYOGLOBULINEMIA; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY DISEASES; KIDNEY GLOMERULUS; PARAPROTEINEMIAS; PARAPROTEINS; THROMBOTIC MICROANGIOPATHIES;

EID: 85017986151     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02980316     Document Type: Article

References (118)

1. Kyle RA: Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 64: 814-826, 1978
2. Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, Picken MM, Herrera GA, Kastritis E, Merlini G, Roussel M, Fervenza FC, Dispenzieri A, Kyle RA, Nasr SH; International Kidney and Monoclonal Gammopathy Research Group: Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 87: 698-711, 2015
3. Confalonieri R, Barbiano di Belgiojoso G, Banfi G, Ferrario F, Bertani T, Pozzi C, Casanova S, Lupo A, De Ferrari G, Minetti L: Light chain nephropathy: Histological and clinical aspects in 15 cases. Nephrol Dial Transplant 3: 150-156, 1988
4. Tubbs RR, Gephardt GN, McMahon JT, Hall PM, Valenzuela R, Vidt DG: Light chain nephropathy. Am J Med 71: 263-269, 1981
5. Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR: Monoclonal immunoglobulin deposition disease: Light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 112: 455-464, 1990
6. Daliani D, Weber D, Alexanian R: Light-heavy chain deposition disease progressing to multiple myeloma. Am J Hematol 50: 296-298, 1995
7. Kambham N, Markowitz GS, Appel GB, Kleiner MJ, Aucouturier P, D’agati VD: Heavy chain deposition disease: The disease spectrum. Am J Kidney Dis 33: 954-962, 1999
8. Aucouturier P, Khamlichi AA, Touchard G, Justrabo E, Cogne M, Chauffert B, Martin F, Preud’homme JL: Brief report: Heavychain deposition disease. N Engl J Med 329: 1389-1393, 1993
9. Tubbs RR, Berkley V, Valenzuela R, McMahon JT, Gephardt GN, Fishleder AJ, Nally JV, Pohl MA, Bukowski RM, Lichtin AE: Pseudo-gamma heavy chain (IgG4 lambda) deposition disease. Mod Pathol 5: 185-190, 1992
10. Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, Eladari D: Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 13: 1438-1445, 1998
11. Denoroy L, Déret S, Aucouturier P: Overrepresentation of the V kappa IV subgroup in light chain deposition disease. Immunol Lett 42: 63-66, 1994
12. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D’Agati VD: Renal monoclonal immunoglobulin deposition disease: The disease spectrum. J AmSoc Nephrol 12: 1482-1492, 2001
13. Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D’Agati VD, Leung N: Renal monoclonal immunoglobulin deposition disease: A report of 64 patients from a single institution. Clin J Am Soc Nephrol 7: 231-239, 2012
14. Pozzi C, Fogazzi GB, Banfi G, Strom EH, Ponticelli C, Locatelli F: Renal disease and patient survival in light chain deposition disease. Clin Nephrol 43: 281-287, 1995
15. Zand L, Nasr SH, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Kumar S, Kyle RA, Fervenza FC, Sethi S, Dingli D, Rajkumar SV, Kapoor P, McCurdy A, Leung N: Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leuk Lymphoma 56: 3357-3364, 2015
16. Moulin B, Deret S, Mariette X, Kourilsky O, Imai H, Dupouet L, Marcellin L, Kolb I, Aucouturier P, Brouet JC, Ronco PM, Mougenot B: Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1. J Am Soc Nephrol 10: 519-528, 1999
17. Alexander MP, Nasr SH, Watson DC, Méndez GP, Rennke HG: Renal crescentic alpha heavy chain deposition disease: A report of 3 cases and review of the literature. Am J Kidney Dis 58: 621-625, 2011
18. Cohen C, Royer B, Javaugue V, Szalat R, El Karoui K, Caulier A, Knebelmann B, Jaccard A, Chevret S, Touchard G, Fermand JP, Arnulf B, Bridoux F: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 88: 1135-1143, 2015
19. Sicard A, Karras A, Goujon JM, Sirac C, Bender S, Labatut D, Callard P, Sarkozy C, Essig M, Vanhille P, Provot F, Nony A, Nochy D, Ronco P, Bridoux F, Touchard G: Light chain deposition disease without glomerular proteinuria: A diagnostic challenge for the nephrologist. Nephrol Dial Transplant 29: 1894-1902, 2014
20. Randall RE, Williamson WC Jr., Mullinax F, Tung MY, Still WJ: Manifestations of systemic light chain deposition. Am JMed 60: 293-299, 1976
21. Strøm EH, Fogazzi GB, Banfi G, Pozzi C, Mihatsch MJ: Light chain deposition disease of the kidney. Morphological aspects in 24 patients. Virchows Arch 425: 271-280, 1994
22. Qian Q, Leung N, Theis JD, Dogan A, Sethi S: Coexistence of myeloma cast nephropathy, light chain deposition disease, and nonamyloid fibrils in a patient with multiple myeloma. Am J Kidney Dis 56: 971-976, 2010
23. Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos MA: Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 94: 300-302, 2009
24. Tovar N, Cibeira MT, Rosiñol L, Solé M, de Larrea CF, Escoda L, Rovira M, Bladé J: Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease. Eur J Haematol 89: 340-344, 2012
25. Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA: Longterm follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 20: 34-41, 1992
26. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R, Henderson K, Kyle RA, Oken MM, Bradwell AR, Greipp PR: Appraisal of immunoglobulin free light chain as a marker of response. Blood 111: 4908-4915, 2008
27. Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, Nadasdy T, D’Agati VD: Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 20: 2055-2064, 2009
28. Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP, Noel LH, Callard P, Delahousse M, Ronco P: Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: Correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 6: 1609-1616, 2011
29. Barbour SJ, Beaulieu MC, Zalunardo NY, Magil AB: Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases. Nephrol Dial Transplant 26: 2712-2714, 2011
30. Fujita E, Shimizu A, Kaneko T, Masuda Y, Ishihara C, Mii A, Higo S, Kajimoto Y, Kanzaki G, Nagasaka S, Iino Y, Katayama Y, Fukuda Y: Proliferative glomerulonephritis with monoclonal immunoglobulin G3k deposits in association with parvovirus B19 infection. Hum Pathol 43: 2326-2333, 2012
31. Fujiwara T, Komatsuda A, Ohtani H, Togashi M, Sawada K, Wakui H: Proliferative glomerulonephritis with monoclonal IgG deposits in a patient with autoimmune hemolytic anemia. Clin Nephrol 79: 494-498, 2013
32. Bhutani G, Nasr SH, Said SM, Sethi S, Fervenza FC, Morice WG, Kurtin PJ, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Lacy MQ, Kapoor P, Kumar S, Kyle RA, Rajkumar SV, Leung N: Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc 90: 587-596, 2015
33. Fatima R, Jha R, Gowrishankar S, Narayen G, Rao BS: Proliferative glomerulonephritis associated with monoclonal immune deposits: A case report and review of literature. Indian J Nephrol 24: 376-379, 2014
34. Nasr SH, Sethi S, Cornell LD, Fidler ME, Boelkins M, Fervenza FC, Cosio FG, D’Agati VD: Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol 6: 122-132, 2011
35. Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F: Primary glomerulonephritis with isolated C3 deposits: A new entity which shares common genetic risk factors with haemolytic uraemic syndrome. JMed Genet 44: 193-199, 2007
36. Pickering MC, D’Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT: C3 glomerulopathy: Consensus report. Kidney Int 84: 1079-1089, 2013
37. Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grü nfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V: Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82: 454-464, 2012
38. Sethi S, Fervenza FC, Zhang Y, Zand L, Meyer NC, Borsa N, Nasr SH, Smith RJ: Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 83: 293-299, 2013
39. Zand L, Kattah A, Fervenza FC, Smith RJ, Nasr SH, Zhang Y, Vrana JA, Leung N, Cornell LD, Sethi S: C3 glomerulonephritis associated with monoclonal gammopathy: A case series. Am J Kidney Dis 62: 506-514, 2013
40. Bridoux F, Desport E, Frémeaux-Bacchi V, Chong CF, Gombert JM, Lacombe C, Quellard N, Touchard G: Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: A fortuitous association? Clin J Am Soc Nephrol 6: 2165-2174, 2011
41. Sepandj F, Trillo A: Dense deposit disease in association with monoclonal gammopathy of unknown significance. Nephrol Dial Transplant 11: 2309-2312, 1996
42. Meri S, Koistinen V, Miettinen A, Törnroth T, Seppälä IJ: Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 175: 939-950, 1992
43. Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S: Nephritogenic lambda light chain dimer: A unique human miniautoantibody against complement factor H. J Immunol 163: 4590-4596, 1999
44. Sethi S, Sukov WR, Zhang Y, Fervenza FC, Lager DJ, Miller DV, Cornell LD, Krishnan SG, Smith RJ: Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 56: 977-982, 2010
45. Larsen CP, Messias NC, Walker PD, Fidler ME, Cornell LD, Hernandez LH, Alexander MP, Sethi S, Nasr SH: Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 88: 867-873, 2015
46. Messias NC, Walker PD, Larsen CP: Paraffin immunofluorescence in the renal pathology laboratory: More than a salvage technique. Mod Pathol 28: 854-860, 2015
47. Daina E, Noris M, Remuzzi G: Eculizumab in a patient with dense-deposit disease. N Engl J Med 366: 1161-1163, 2012
48. McCaughan JA, O’Rourke DM, Courtney AE: Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies. Am J Transplant 12: 1046-1051, 2012
49. Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D’Agati VD, Canetta PA, Radhakrishnan J, Appel GB: Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7: 748-756, 2012
50. Vivarelli M, Pasini A, Emma F: Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366: 1163-1165, 2012
51. Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van denHeuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ, Groothoff JW: Eculizumab in pediatric dense deposit disease. Clin J Am Soc Nephrol 10: 1773-1782, 2015
52. Inman M, Prater G, Fatima H, Wallace E: Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. Clin Kidney J 8: 445-448, 2015
53. Payette A, Patey N, Dragon-Durey MA, Frémeaux-Bacchi V, Le Deist F, Lapeyraque AL: A case of C3 glomerulonephritis successfully treated with eculizumab. Pediatr Nephrol 30: 1033-1037, 2015
54. Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, Goujon JM, Frémeaux-Bacchi V, Fakhouri F: Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 65: 484-489, 2015
55. Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M: Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 29: 1107-1111, 2014
56. Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, Herrera Hernandez L, Vrana JA, Theis JD, Quint PS, Dogan A, Nasr SH: Renal amyloidosis: Origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 8: 1515-1523, 2013
57. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM, Kurland LT: Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79: 1817-1822, 1992
58. Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA: Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 84: 440-451, 2004
59. Teng J, Turbat-Herrera EA, Herrera GA: Role of translational research advancing the understanding of the pathogenesis of light chain-mediated glomerulopathies. Pathol Int 57: 398-412, 2007
60. Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Vidus Rosin M, Albertini R, Moratti R, Merlini G, Schönland S: A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124: 2325-2332, 2014
61. Nasr SH, Said SM, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, Dispenzieri A, Buadi FK, Vrana JA, Theis JD, Dogan A, Leung N: The diagnosis and characteristics of renal heavychain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int 83: 463-470, 2013
62. Wechalekar AD, Gillmore JD, Hawkins PN: Systemic amyloidosis [published online ahead of print December 21, 2015]. Lancet doi:10.1016/S0140-6736(15)01274-X
63. Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, Perlini S, Albertini R, Russo P, Foli A, Bragotti LZ, Obici L, Moratti R, Melzi d’Eril GV, Merlini G: The combination of highsensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116: 3426-3430, 2010
64. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 22: 3751-3757, 2004
65. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN: Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. NEngl J Med 346: 1786-1791, 2002
66. Sethi S, Vrana JA, Theis JD, Leung N, Sethi A, Nasr SH, Fervenza FC, Cornell LD, Fidler ME, Dogan A: Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 82: 226-234, 2012
67. Leung N, Nasr SH, Sethi S: How I treat amyloidosis: The importance of accurate diagnosis and amyloid typing. Blood 120: 3206-3213, 2012
68. Sethi S, Theis JD, Vrana JA, Fervenza FC, Sethi A, Qian Q, Quint P, Leung N, Dogan A, Nasr SH: Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol 8: 915-921, 2013
69. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A: Update on treatment of light chain amyloidosis. Haematologica 99: 209-221, 2014
70. Haider S, Ahmad N, Anaissie E, Driscoll JJ: Future directions in the clinical management of amyloid light-chain amyloidosis. Leuk Lymphoma 55: 2241-2251, 2014
71. Dember LM: Amyloidosis-associated kidney disease. J Am Soc Nephrol 17: 3458-3471, 2006
72. Gertz MA, Lacy MQ, Dispenzieri A: Immunoglobulin light chain amyloidosis and the kidney. Kidney Int 61: 1-9, 2002
73. Leung N, Kumar SK, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Kapoor P, Zeldenrust SR, Russell SJ, Lust JA, Hogan WJ, Rajkumar SV, Gastineau DA, Kourelis TV, Lin Y, Gonsalves WI, Go RS, Gertz MA: The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation [published online ahead of print November 30, 2015]. Nephrol Dial Transplant
74. Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N: Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant 26: 2032-2036, 2011
75. Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, Leung N, Fervenza FC: Fibrillary glomerulonephritis: A report of 66 cases from a single institution. Clin J Am Soc Nephrol 6: 775-784, 2011
76. Rosenstock JL, Markowitz GS, Valeri AM, Sacchi G, Appel GB, D’Agati VD: Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int 63: 1450-1461, 2003
77. Iskandar SS, Falk RJ, Jennette JC: Clinical and pathologic features of fibrillary glomerulonephritis. Kidney Int 42: 1401-1407, 1992
78. Javaugue V, Karras A, Glowacki F, McGregor B, Lacombe C, Goujon JM, Ragot S, Aucouturier P, Touchard G, Bridoux F: Long-term kidney disease outcomes in fibrillary glomerulonephritis: A case series of 27 patients. Am J Kidney Dis 62: 679-690, 2013
79. Fogo A, Qureshi N, Horn RG: Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis 22: 367-377, 1993
80. Fermand JP, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA, Drayson MT, Dispenzieri A, Leung N; International Kidney and Monoclonal Gammopathy Research Group: How I treat monoclonal gammopathy of renal significance (MGRS). Blood 122: 3583-3590, 2013
81. Hogan J, Restivo M, Canetta PA, Herlitz LC, Radhakrishnan J, Appel GB, Bomback AS: Rituximab treatment for fibrillary glomerulonephritis.Nephrol Dial Transplant 29: 1925-1931, 2014
82. Touchard G, Bauwens M, Goujon JM, Aucouturier P, Patte D, Preud’homme JL: Glomerulonephritis with organized microtubular monoclonal immunoglobulin deposits. Adv Nephrol Necker Hosp 23: 149-175, 1994
83. Herrera GA, Ojemakinde KO, Turbat-Herrera EA, Gu X, Zeng X, Iskandar SS: Immunotactoid glomerulopathy and cryoglobulinemic nephropathy: Two entities with many similarities. A unified conceptual approach. Ultrastruct Pathol 39: 270-280, 2015
84. Nasr SH, Fidler ME, Cornell LD, Leung N, Cosio FG, Sheikh SS, Amir AA, Vrana JA, Theis JD, Dogan A, Sethi S: Immunotactoid glomerulopathy: Clinicopathologic and proteomic study. Nephrol Dial Transplant 27: 4137-4146, 2012
85. Bridoux F, Hugue V, Coldefy O, Goujon JM, Bauwens M, Sechet A, Preud’Homme JL, Touchard G: Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 62: 1764-1775, 2002
86. Moulin B, Ronco PM, Mougenot B, Francois A, Fillastre JP, Mignon F: Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 42: 127-135, 1992
87. Pronovost PH, Brady HR, Gunning ME, Espinoza O, Rennke HG: Clinical features, predictors of disease progression and results of renal transplantation in fibrillary/immunotactoid glomerulopathy. Nephrol Dial Transplant 11: 837-842, 1996
88. Castro JE, Diaz-Perez JA, Barajas-Gamboa JS, Horton JM, Weidner N, Kipps TJ: Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: A case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab. Leuk Lymphoma 53: 1835-1838, 2012
89. Ramos-Casals M, Stone JH, Cid MC, Bosch X: The cryoglobulinaemias. Lancet 379: 348-360, 2012
90. Ghetie D, Mehraban N, Sibley CH: Cold hard facts of cryoglobulinemia: Updates on clinical features and treatment advances. Rheum Dis Clin North Am 41: 93-108, 2015
91. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M: Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57: 775-788, 1974
92. Herrera GA, Turbat-Herrera EA: Renal diseases with organized deposits: An algorithmic approach to classification and clinicopathologic diagnosis. Arch Pathol Lab Med 134: 512-531, 2010
93. Payet J, Livartowski J, Kavian N, Chandesris O, Dupin N, Wallet N, Karras A, Salliot C, Suarez F, Avet-Loiseau H, Alyanakian MA, Nawakil CA, Park S, Tamburini J, Roux C, Bouscary D, Sparsa L: Type I cryoglobulinemia in multiple myeloma, a rare entity: Analysis of clinical and biological characteristics of seven cases and review of the literature. Leuk Lymphoma 54: 767-777, 2013
94. Karras A, Noël LH, Droz D, Delansorne D, Saint-André JP, Aucouturier P, Alyanakian MA, Grünfeld JP, Lesavre P: Renal involvement in monoclonal (type I) cryoglobulinemia: Two cases associated with IgG3 kappa cryoglobulin. Am J Kidney Dis 40: 1091-1096, 2002
95. Pais B, Panadés MJ, Ramos J, Montoliu J: Glomerular involvement in type I monoclonal cryoglobulinaemia. Nephrol Dial Transplant 10: 130-132, 1995
96. Terrier B, Krastinova E, Marie I, Launay D, Lacraz A, Belenotti P, de Saint-Martin L, Quemeneur T, Huart A, Bonnet F, Le Guenno G, Kahn JE, Hinschberger O, Rullier P, Diot E, Lazaro E, Bridoux F, Zénone T, Carrat F, Hermine O, Léger JM, Mariette X, Senet P, Plaisier E, Cacoub P: Management of noninfectious mixed cryoglobulinemia vasculitis: Data from 242 cases included in the CryoVas survey. Blood 119: 5996-6004, 2012
97. Néel A, Perrin F, Decaux O, Dejoie T, Tessoulin B, Halliez M, Mahé B, Lamy T, Fakhouri F, Jego P, Agard C, Vigneau C, Guenet L, Grosbois B, Moreau P, Hamidou M: Long-term outcome of monoclonal (type 1) cryoglobulinemia. Am J Hematol 89: 156-161, 2014
98. Bryce AH, Kyle RA, Dispenzieri A, Gertz MA: Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am J Hematol 81: 511-518, 2006
99. Herlitz LC, D’Agati VD, Markowitz GS: Crystalline nephropathies. Arch Pathol Lab Med 136: 713-720, 2012
100. Stokes MB, Valeri AM, Herlitz L, Khan AM, Siegel DS, Markowitz GS, D’Agati VD: Light chain proximal tubulopathy: Clinical and pathologic characteristics in the modern treatment era. J Am Soc Nephrol 27: 1555-1565, 2016
101. Carstens PH, Woo D: Crystalline glomerular inclusions in multiple myeloma. Am J Kidney Dis 14: 56-60, 1989
102. Aucouturier P, Bauwens M, Khamlichi AA, Denoroy L, Spinelli S, Touchard G, Preud’homme JL, CognéM: Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi’s syndrome. J Immunol 150: 3561-3568, 1993
103. Leboulleux M, Lelongt B, Mougenot B, Touchard G, Makdassi R, Rocca A, Noel LH, Ronco PM, Aucouturier P: Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int 48: 72-79, 1995
104. Messiaen T, Deret S, Mougenot B, Bridoux F, Dequiedt P, Dion JJ, Makdassi R, Meeus F, Pourrat J, Touchard G, Vanhille P, Zaoui P, Aucouturier P, Ronco PM: Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore) 79: 135-154, 2000
105. Rocca A, Khamlichi AA, Touchard G, Mougenot B, Ronco P, Denoroy L, Deret S, Preud’homme JL, Aucouturier P, CognéM: Sequences of V kappa L subgroup light chains in Fanconi’s syndrome. Light chain V region gene usage restriction and peculiarities in myeloma-associated Fanconi’s syndrome. J Immunol 155: 3245-3252, 1995
106. Gupta V, El Ters M, Kashani K, Leung N, Nasr SH: Crystalglobulininduced nephropathy. J AmSocNephrol 26: 525-529, 2015
107. Hasegawa H, Ozawa T, Tada N, Taguchi Y, Ohno K, Chou T, Watanabe T, Kuroda T, Nakano M, Usuda H, Emura I, Arakawa M: Multiple myeloma-associated systemic vasculopathy due to crystalglobulin or polyarteritis nodosa. Arthritis Rheum 39: 330-334, 1996
108. Leung N, Buadi FK, Song KW, Magil AB, Cornell LD: A case of bilateral renal arterial thrombosis associated with cryocrystalglobulinaemia. NDT Plus 3: 74-77, 2010
109. Stone GC, Wall BA, Oppliger IR, Wener MH, Jolly SL, Aguirre A, Dwyer R, Simkin PA: Avasculopathy with deposition of lambda light chain crystals. Ann Intern Med 110: 275-278, 1989
110. Taccone FS, Bouko Y, Robin V: Exceptional association of diffuse anaplastic myeloma with microangiopathic anemia. Eur J Intern Med 18: 607, 2007
111. Alpay N, Uzun S, Bahat G, Yavuz S, Erten N, Tascioglu C: Thrombotic thrombocytopenic purpura associated with multiple myeloma. Blood Coagul Fibrinolysis 19: 439-441, 2008
112. Yao H, Monge M, Renou M, Lecaque C, Jauréguy M, Presne C, Makdassi R, Choukroun G: Thrombotic thrombocytopenic purpura due to anti-ADAMTS13 antibodies in multiple myeloma. Clin Nephrol 81: 210-215, 2014
113. Xiao X, Zhong HY, Zhang GS, Deng MY: Thrombotic thrombocytopenic purpura as initial and major presentation of multiple myeloma. J Thromb Thrombolysis 36: 422-423, 2013
114. Lodhi A, Kumar A, Saqlain MU, Suneja M: Thrombotic microangiopathy associated with proteasome inhibitors. Clin Kidney J 8: 632-636, 2015
115. Kornacker M, Luft T, Ho AD, Schaefer HJ: Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma-report of three cases. Eur J Haematol 74: 250-253, 2005
116. Hofmeister CC, Jin M, Cataland SR, Benson DM, Wu HM: TTP disease course is independent of myeloma treatment and response. Am J Hematol 85: 304-306, 2010
117. Kanjanabuch T, Bunruang R, Srisawat N, Lewsuwan S, Kittikovit V, Eiam-Ong S: The combination of thrombotic microangiopathy and nodular sclerosis in light chain deposition disease. J Med Assoc Thai 89[Suppl 2]: S248-S252, 2006
118. Larsen CP, Ambuzs JM, Bonsib SM, Boils CL, Cossey LN, Messias NC, Silva FG, Wang YH, Gokden N, Walker PD: Membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int 86: 154-161, 2014